Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AL 8326

Next Previous
Drug Profile

AL 8326

Alternative Names: AL-8326

Latest Information Update: 15 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase B inhibitors; Fibroblast growth factor receptor antagonists; MTOR protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 01 Sep 2026 Advenchen Laboratories plans a phase Ib/IIa trial for Breast cancer, Soft tissue sarcoma, Endometrial cancer, Cervical cancer (Combination therapy, Late stage disease, Metastatic disease, Second line therapy or greater, Recurrent) in USA (PO) (NCT07811232)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
  • 15 May 2025 Advenchen Laboratories Nanjing completes a phase I trial for Small cell lung cancer (In volunteers) in China (NCT07132957)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top